Jan 19 2026

george

The Value of Offering DOAC Measurements

Obtain this article from your medical library: Swan D, Roberts L, Thachil J. In a nutshell: testing DOAC levels-when, why and what it means? Br J Haematol. 2026. doi: 10.1111/bjh.70313. PMID: 41482473. Abstract Plasma direct oral anticoagulant (DOAC) levels are not routinely required for the majority of patients; however, they may provide valuable information in […]

read more

Comments (0)

Anticoagulant Therapy

Jan 14 2026

george

Cohort Study: Do Anticonvulsants Interfere with DOAC Therapy?

Navigate to this open-access population cohort study of the effects of anticonvulsants when used during DOAC Rx: Carlin S, Holbrook AM, Candeloro M, et al. Association of direct oral anticoagulant-anticonvulsant coprescription with clinical outcomes in older adults: a population-based cohort study. J Thromb Haemost. 2025:S1538-7836(25)00727-5. doi: 10.1016/j.jtha.2025.10.027. PMID: 41207565. Abstract Background: Anticonvulsants vary in their […]

read more

Comments (0)

Anticoagulant Therapy

Jan 9 2026

george

Anticoagulation Forum Archived Webinars

Fifth on our alphabetical Hemostasis Agencies list is the Anticoagulation Forum. The forum offers a lengthy list of archived educational webinars that describe a number of antithrombotic therapy issues. Click here for the forum’s webinar selection.

read more

Comments (0)

Anticoagulant Therapy

Dec 29 2025

george

Andexanet Alfa Withdrawn from the US Market

Thanks for the heads-up from Dr. Paul Riley, who commented on our December 27, 2025, post, Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal. Here is the press release from AstraZeneca announcing the withdrawal of andexanet alfa from the US market.

read more

Comments (0)

Blog

Dec 27 2025

george

Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal

Navigate to this open-access article describing andexanet alfa reversal of LMWH: van Haaps TF, Benz AP, Xu L, Middeldorp S, Eikelboom JW, et al. Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin. Res Pract Thromb Haemost. 2025;9:103191. doi: 10.1016/j.rpth.2025.103191. PMID: 41141842; PMCID: PMC12552982. Abstract Background Andexanet alfa (andexanet) is the only approved reversal […]

read more

Comments (1)

Anticoagulant Therapy

Dec 26 2025

george

August 2025 CAP Today: D-dimer Reporting and INR Are Variables That Matter

In follow-up to their July 2025 CAP Today article, A Deep Dive into Key Hemostasis Testing Variables, Drs. Andrew Goodwin and Eric Salazar present external quality improvement data on the PT–INR, D-dimer, and VET in their August 2025 article, D-dimer Reporting and INR Are Variables That Matter. Their article in particular examines the confusion over […]

read more

Comments (0)

Anticoagulant Therapy

Dec 9 2025

george

Diagnostic Equity Case: Varying INR

This question came from a patient to the Diagnostic Equity Service on 12-9-2025: I notice my INR keeps changing even though I take the same warfarin dose. Could this be a lab issue or a metabolism issue? Thank you for what you do. Abby Carroll, MS, MLS (ASCP)cm answered: In most cases, INR variability is […]

read more

Comments (0)

Anticoagulant Therapy

Dec 8 2025

george

Asundexian Anti-XIa Antithrombotic Shows Promise

Select “Bayer’s Asundexian anti XIa antithrombin met primary efficacy and safety endpoints in a landmark phase III OCEANIC-STROKE study for secondary stroke prevention” for their press release presented at ASH 2025.  

read more

Comments (0)

Anticoagulant Therapy

Dec 8 2025

george

A Coag Conversation: Alternate Warfarin Monitoring When the Prothrombin Time is Unreliable – Part 3: DOACs and Warfarin

Join me (Geo) and guest speaker Dr. Nicole Zantek, MD, PhD, Medical Director of the Special Coagulation Laboratory and Professor, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, as we discuss the pathophysiology of antiphospholipid antibodies and alternative methods to monitor warfarin and DOAC anticoagulation in patients diagnosed with APS. Click DOACs […]

read more

Comments (1)

Anticoagulant Therapy

Nov 24 2025

george

11-8-25 AHA Presentation Records Successful Reduction of Anticoagulation in AFIB

Click here for the results of a “One month of clot prevention after a stent was as effective as a Year-long course for AFIB.” Research Highlights: A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who received […]

read more

Comments (0)

Anticoagulant Therapy